{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:00:35Z","timestamp":1761872435344,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.clml.2023.08.005","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T12:23:02Z","timestamp":1691583782000},"page":"e393-e404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-6710","authenticated-orcid":false,"given":"John M.","family":"Burke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Masaquel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6577-0762","authenticated-orcid":false,"given":"Farah","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3937-5913","authenticated-orcid":false,"given":"Summera Qiheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen D.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-3721","authenticated-orcid":false,"given":"Matthew","family":"Matasar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.08.005_bib0001","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.08.005_bib0002","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.08.005_bib0003","unstructured":"National Cancer Institute (NCI) Surveillance Epidemiology and End Results Program. Cancer stat facts: NHL \u2013 diffuse large B-cell lymphoma (DLBCL) 2019. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html. Accessed: September 5, 2023."},{"key":"10.1016\/j.clml.2023.08.005_bib0004","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025","volume":"63","author":"Kanas","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.08.005_bib0005","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.08.005_bib0006","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1200\/JCO.2017.74.7360","article-title":"Succeeding in breaking the R-CHOP ceiling in DLBCL: learning from negative trials","volume":"35","author":"Goy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.08.005_bib0007","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/14737167.2019.1680288","article-title":"Cost burden of diffuse large B-cell lymphoma","volume":"19","author":"Harkins","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clml.2023.08.005_bib0008","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1080\/10428194.2018.1459613","article-title":"Costs of relapsed diffuse large B-cell lymphoma among Medicare patients","volume":"59","author":"Huntington","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.08.005_bib0009","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1634\/theoncologist.2018-0490","article-title":"Direct costs associated with relapsed diffuse large B-cell lymphoma therapies","volume":"24","author":"Purdum","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2023.08.005_bib0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529684","article-title":"Matching to remove bias in observational studies","volume":"29","author":"Rubin","year":"1973","journal-title":"Biometrics"},{"key":"10.1016\/j.clml.2023.08.005_bib0011","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2307\/2529981","article-title":"Bias reduction using Mahalanobis-metric matching","volume":"36","author":"Rubin","year":"1980","journal-title":"Biometrics"},{"key":"10.1016\/j.clml.2023.08.005_bib0012","unstructured":"US Bureau of Labor Statistics. Consumer Price Index Archived News Releases. Updated 16 February 2023. Available at: https:\/\/www.bls.gov\/bls\/news-release\/cpi.htm. Accessed: March 7, 2023."},{"key":"10.1016\/j.clml.2023.08.005_bib0013","unstructured":"European Medicines Agency. Yescarta\u24c7 Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yescarta-epar-product-information_en.pdf. Accessed: April 6, 2023."},{"key":"10.1016\/j.clml.2023.08.005_bib0014","unstructured":"European Medicines Agency. Kymriah\u24c7 Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kymriah-epar-product-information_en.pdf. Accessed: April 6, 2023."},{"key":"10.1016\/j.clml.2023.08.005_bib0015","unstructured":"US Food and Drug Administration. YESCARTA\u24c7 US Prescribing Information. Available at: https:\/\/www.fda.gov\/media\/108377\/download. Accessed: April 6, 2023."},{"key":"10.1016\/j.clml.2023.08.005_bib0016","unstructured":"US Food and Drug Administration. KYMRIAH\u24c7 US Prescribing Information. Available at: https:\/\/www.fda.gov\/media\/107296\/download. Accessed April 6, 2023."},{"key":"10.1016\/j.clml.2023.08.005_bib0017","unstructured":"US Food and Drug Administration. BREYANZI\u24c7 US Prescribing Information. Available at: https:\/\/www.fda.gov\/media\/145711\/download. Accessed April 6, 2023."},{"key":"10.1016\/j.clml.2023.08.005_bib0018","unstructured":"European Medicines Agency. Breyanzi\u24c7 Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/breyanzi-epar-product-information_en.pdf. Accessed April 6, 2023."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:18Z","timestamp":1761871398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023002537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2152265023002537"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}